Researchers Linked Immune Cell Genes to Alzheimer's
A new genetic study has identified specific immune cell subsets that contribute to Alzheimer's disease susceptibility.
Updated on Oct. 2, 2026 in Alzheimer’s
Live Poll
Do you believe finding new treatments for Alzheimer's disease should be a top national research priority?
Scientists have uncovered a connection between Alzheimer's disease and specific gene expressions within naive/central memory T-cells and monocyte-related populations. This integration of genetic and immune data provides new targets for understanding how immune dysregulation influences the progression of the condition.
Why it matters
Immune system dysfunction is increasingly recognized as a major driver of Alzheimer's pathology. By identifying the exact cell types involved, researchers can better map how genetic risk signals translate into the cognitive decline characteristic of the disease.
Researchers prioritized candidate genes such as KANSL1-AS1, CTSH, and JAZF1 by integrating OneK1K immune cell-specific cis-eQTL data with Alzheimer's genome-wide association study signals. The clinical effectiveness of these targets is not yet confirmed.
The players
OneK1K
This is an extensive research resource providing high-resolution single-cell expression quantitative trait loci data across diverse human immune cell types.
The details
The research team utilized sophisticated methodologies including two-sample Mendelian randomization and Bayesian colocalization to link genetic signals to specific immune cell types. Peripheral blood single-cell RNA sequencing further characterized how these genes are expressed, generating new hypotheses for drug repurposing to address Alzheimer's.
Timeline
October 2, 2026: The peer-reviewed research article was published online.
The Big Picture
This study advances the use of the OneK1K resource by applying its high-resolution genetic data to the specific, complex landscape of neurodegenerative disease susceptibility. It follows a growing pattern of using multi-omic datasets to move beyond broad genetic associations toward precise cellular mechanisms.
This research creates a new pipeline for identifying potential drug repurposing candidates that could lead to future Alzheimer's treatments. While these findings do not change daily care routines today, they establish the scientific foundation necessary for developing more targeted precision therapies.
The takeaway
The discovery of immune cell-specific genetic drivers offers a roadmap for moving from broad genomic data to concrete therapeutic targets. Researchers must now focus on rigorous experimental testing to determine if these gene candidates can effectively slow or prevent neurodegeneration.
Further reading
For more on the current state of neurodegenerative research, visit our Alzheimer’s section.
More information
Access the full peer-reviewed research article to review the detailed methodology and gene prioritization results.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe finding new treatments for Alzheimer's disease should be a top national research priority?
